Skip to main content
Erschienen in: Journal of Gastrointestinal Cancer 3/2020

25.11.2019 | Original Research

Overexpression and Clinicopathological Correlation of Long Noncoding RNA TMPO-AS1 in Colorectal Cancer Patients

verfasst von: Haniye Mohammadrezakhani, Behzad Baradaran, Dariush Shanehbandi, Milad Asadi, Shahriar Hashemzadeh, Khalil Hajiasgharzadeh, Reza Safaralizadeh

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Long noncoding RNA (lncRNA) has been identified as an important modulator of gene expression and other activities of the cells. This kind of genes also has a significant role in the growth and development of human cancers, including colorectal cancer (CRC). Among lncRNAs, thymopoietin (TMPO)-antisense RNA 1 (TMPO-AS1) is of particular significance and might have a role in CRC regulation. The current study aimed to determine the involvement of TMPO-AS1 in CRC patients.

Methods

In this study, 50 pairs of tumor and tumor marginal samples of CRC patients were investigated to assess the expression level of TMPO-AS1 in this cancer. For this purpose, the total RNA was isolated from the tissues using the TRIzol RNA extraction method, and after synthesis of the complementary DNA, the TMPO-AS1 expression was measured by quantitative real-time PCR (qRT-PCR) technique. In addition, clinicopathological characteristics of the CRC patients were analyzed in the study groups.

Results

The findings demonstrated the overexpression of TMPO-AS1 in CRC tissues. Interestingly, the expression level of TMPO-AS1 was significantly correlated with clinicopathological features of the patients such as lymph node and distant metastasis.

Conclusion

The overexpression of TMPO-AS1 gene in CRC suggests that this lncRNA and its underlying signaling pathways can be considered a prognostic tumor marker and may pave the way for the future development of novel therapeutic options for CRC.
Literatur
1.
Zurück zum Zitat Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67:177–93.CrossRef Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67:177–93.CrossRef
2.
Zurück zum Zitat Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-tieulent J, Jemal A. Global Cancer statistics, 2012. CA a cancer J Clin. 2015;65:87–108.CrossRef Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-tieulent J, Jemal A. Global Cancer statistics, 2012. CA a cancer J Clin. 2015;65:87–108.CrossRef
3.
Zurück zum Zitat Shirafkan N, Mansoori B, Mohammadi A, Shomali N, Ghasbi M, Baradaran B. MicroRNAs as novel biomarkers for colorectal cancer: new outlooks. Biomed Pharmacother Elsevier. 2018;97:1319–30.CrossRef Shirafkan N, Mansoori B, Mohammadi A, Shomali N, Ghasbi M, Baradaran B. MicroRNAs as novel biomarkers for colorectal cancer: new outlooks. Biomed Pharmacother Elsevier. 2018;97:1319–30.CrossRef
4.
Zurück zum Zitat Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 2009;22:191–7.CrossRef Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 2009;22:191–7.CrossRef
5.
Zurück zum Zitat Sadreddini S, Safaralizadeh R, Baradaran B, Aghebati-Maleki L, Hosseinpour-Feizi MA, Shanehbandi D, et al. Chitosan nanoparticles as a dual drug/siRNA delivery system for treatment of colorectal cancer. Immunol Lett. Elsevier B.V.; 2017;181:79–86. Sadreddini S, Safaralizadeh R, Baradaran B, Aghebati-Maleki L, Hosseinpour-Feizi MA, Shanehbandi D, et al. Chitosan nanoparticles as a dual drug/siRNA delivery system for treatment of colorectal cancer. Immunol Lett. Elsevier B.V.; 2017;181:79–86.
6.
Zurück zum Zitat Hallaj-Nezhadi S, Valizadeh H, Dastmalchi S, Baradaran B, Jalali MB, Dobakhti F, et al. Preparation of chitosan-plasmid DNA nanoparticles encoding interleukin-12 and their expression in CT-26 colon carcinoma cells. J Pharm Pharm Sci. 2011;14:181–95.CrossRef Hallaj-Nezhadi S, Valizadeh H, Dastmalchi S, Baradaran B, Jalali MB, Dobakhti F, et al. Preparation of chitosan-plasmid DNA nanoparticles encoding interleukin-12 and their expression in CT-26 colon carcinoma cells. J Pharm Pharm Sci. 2011;14:181–95.CrossRef
7.
Zurück zum Zitat Xie F, Xiang X, Huang Q, Ran P, Yuan Y, Li Q, et al. Reciprocal control of lncRNA-BCAT1 and β-catenin pathway reveals lncRNA-BCAT1 long non-coding RNA acts as a tumor suppressor in colorectal cancer. Oncotarget. 2017;8:23628–37.CrossRef Xie F, Xiang X, Huang Q, Ran P, Yuan Y, Li Q, et al. Reciprocal control of lncRNA-BCAT1 and β-catenin pathway reveals lncRNA-BCAT1 long non-coding RNA acts as a tumor suppressor in colorectal cancer. Oncotarget. 2017;8:23628–37.CrossRef
8.
Zurück zum Zitat Kazemzadeh M, Safaralizadeh R, Feizi MAH, Somi MH, Shokoohi B. Misregulation of the dependence receptor DCC and its upstream lincRNA, LOC100287225, in colorectal cancer. Tumori J. 2017;103:40–3.CrossRef Kazemzadeh M, Safaralizadeh R, Feizi MAH, Somi MH, Shokoohi B. Misregulation of the dependence receptor DCC and its upstream lincRNA, LOC100287225, in colorectal cancer. Tumori J. 2017;103:40–3.CrossRef
9.
Zurück zum Zitat Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell. Elsevier Inc.; 2009;136:629–41. Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell. Elsevier Inc.; 2009;136:629–41.
10.
Zurück zum Zitat Peng WX, Koirala P, Mo YY. LncRNA-mediated regulation of cell signaling in cancer. Oncogene. 2017;36:5661–7.CrossRef Peng WX, Koirala P, Mo YY. LncRNA-mediated regulation of cell signaling in cancer. Oncogene. 2017;36:5661–7.CrossRef
11.
Zurück zum Zitat Jarroux J, Morillon A, Pinskaya M. History, discovery, and classification of lncRNAs. Adv Exp Med Biol. 2017. p. 1–46. Jarroux J, Morillon A, Pinskaya M. History, discovery, and classification of lncRNAs. Adv Exp Med Biol. 2017. p. 1–46.
12.
Zurück zum Zitat Brosnan CA, Voinnet O. The long and the short of noncoding RNAs. Curr Opin Cell Biol. 2009;21:416–25.CrossRef Brosnan CA, Voinnet O. The long and the short of noncoding RNAs. Curr Opin Cell Biol. 2009;21:416–25.CrossRef
13.
Zurück zum Zitat Huang W, Su X, Yan W, Kong Z, Wang D, Huang Y, et al. Overexpression of AR-regulated lncRNA TMPO-AS1 correlates with tumor progression and poor prognosis in prostate cancer. Prostate. 2018;78:1248–61.CrossRef Huang W, Su X, Yan W, Kong Z, Wang D, Huang Y, et al. Overexpression of AR-regulated lncRNA TMPO-AS1 correlates with tumor progression and poor prognosis in prostate cancer. Prostate. 2018;78:1248–61.CrossRef
14.
Zurück zum Zitat Peng F, Wang R, Zhang Y, Zhao Z, Zhou W, Chang Z, et al. Differential expression analysis at the individual level reveals a lncRNA prognostic signature for lung adenocarcinoma. Mol Cancer Molecular Cancer. 2017;16:1–12.CrossRef Peng F, Wang R, Zhang Y, Zhao Z, Zhou W, Chang Z, et al. Differential expression analysis at the individual level reveals a lncRNA prognostic signature for lung adenocarcinoma. Mol Cancer Molecular Cancer. 2017;16:1–12.CrossRef
15.
Zurück zum Zitat Zhang L, Wang G, Chen S, Ding J, Ju S, Cao H, et al. Depletion of thymopoietin inhibits proliferation and induces cell cycle arrest/apoptosis in glioblastoma cells. World J Surg Oncol World Journal of Surgical Oncology. 2016;14:1–8. Zhang L, Wang G, Chen S, Ding J, Ju S, Cao H, et al. Depletion of thymopoietin inhibits proliferation and induces cell cycle arrest/apoptosis in glioblastoma cells. World J Surg Oncol World Journal of Surgical Oncology. 2016;14:1–8.
16.
Zurück zum Zitat Brachner A, Foisner R. Lamina-associated polypeptide (LAP)2α and other LEM proteins in cancer biology. 2014. p. 143–63. Brachner A, Foisner R. Lamina-associated polypeptide (LAP)2α and other LEM proteins in cancer biology. 2014. p. 143–63.
17.
Zurück zum Zitat Siahmansouri H, Somi MH, Babaloo Z, Baradaran B, Jadidi-Niaragh F, Atyabi F, et al. Effects of HMGA2 siRNA and doxorubicin dual delivery by chitosan nanoparticles on cytotoxicity and gene expression of HT-29 colorectal cancer cell line. J Pharm Pharmacol. 2016:1119–30. Siahmansouri H, Somi MH, Babaloo Z, Baradaran B, Jadidi-Niaragh F, Atyabi F, et al. Effects of HMGA2 siRNA and doxorubicin dual delivery by chitosan nanoparticles on cytotoxicity and gene expression of HT-29 colorectal cancer cell line. J Pharm Pharmacol. 2016:1119–30.
18.
Zurück zum Zitat Daryabari SS, Safaralizadeh R, Hosseinpourfeizi M, Moaddab Y, Shokouhi B. Overexpression of SSH1 in gastric adenocarcinoma and its correlation with clinicopathological features. J Gastrointest Oncol. 2018;9:728–33.CrossRef Daryabari SS, Safaralizadeh R, Hosseinpourfeizi M, Moaddab Y, Shokouhi B. Overexpression of SSH1 in gastric adenocarcinoma and its correlation with clinicopathological features. J Gastrointest Oncol. 2018;9:728–33.CrossRef
19.
Zurück zum Zitat Djebali S, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A, et al. Landscape of transcription in human cells. Nature. 2012;489:101–8.CrossRef Djebali S, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A, et al. Landscape of transcription in human cells. Nature. 2012;489:101–8.CrossRef
20.
Zurück zum Zitat Ong MS, Cai W, Tan TZ, Huang RY, Hooi SC, Yap CT, et al. Long non-coding RNA landscape in colorectal cancer. Rna Dis. 2018;5:1–9. Ong MS, Cai W, Tan TZ, Huang RY, Hooi SC, Yap CT, et al. Long non-coding RNA landscape in colorectal cancer. Rna Dis. 2018;5:1–9.
21.
Zurück zum Zitat Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer Res. 2017;77:3965–81.CrossRef Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer Res. 2017;77:3965–81.CrossRef
22.
Zurück zum Zitat Chen G, Wang Z, Wang D, Qiu C, Liu M, Chen X, et al. LncRNA disease: a database for long-non-coding RNA-associated diseases. Nucleic Acids Res. 2013;41:983–6.CrossRef Chen G, Wang Z, Wang D, Qiu C, Liu M, Chen X, et al. LncRNA disease: a database for long-non-coding RNA-associated diseases. Nucleic Acids Res. 2013;41:983–6.CrossRef
23.
Zurück zum Zitat Schmitt AM, Chang HY. Long noncoding rnas in cancer pathways. Cancer Cell. Elsevier Inc.; 2016;29:452–63. Schmitt AM, Chang HY. Long noncoding rnas in cancer pathways. Cancer Cell. Elsevier Inc.; 2016;29:452–63.
24.
Zurück zum Zitat Qin Z, Zheng X, Fang Y. Long noncoding RNA TMPO-AS1 promotes progression of non-small cell lung cancer through regulating its natural antisense transcript TMPO. Biochem Biophys Res Commun Elsevier Ltd. 2019;516:486–93.CrossRef Qin Z, Zheng X, Fang Y. Long noncoding RNA TMPO-AS1 promotes progression of non-small cell lung cancer through regulating its natural antisense transcript TMPO. Biochem Biophys Res Commun Elsevier Ltd. 2019;516:486–93.CrossRef
Metadaten
Titel
Overexpression and Clinicopathological Correlation of Long Noncoding RNA TMPO-AS1 in Colorectal Cancer Patients
verfasst von
Haniye Mohammadrezakhani
Behzad Baradaran
Dariush Shanehbandi
Milad Asadi
Shahriar Hashemzadeh
Khalil Hajiasgharzadeh
Reza Safaralizadeh
Publikationsdatum
25.11.2019
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Cancer / Ausgabe 3/2020
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-019-00333-7

Weitere Artikel der Ausgabe 3/2020

Journal of Gastrointestinal Cancer 3/2020 Zur Ausgabe

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

03.06.2024 NSCLC Nachrichten

Wie stark Menschen mit fortgeschrittenem NSCLC von einer Therapie mit Immun-Checkpoint-Hemmern profitieren, hängt offenbar auch davon ab, wie sehr die Diagnose ihre psychische Verfassung erschüttert

Antikörper mobilisiert Neutrophile gegen Krebs

03.06.2024 Onkologische Immuntherapie Nachrichten

Ein bispezifischer Antikörper formiert gezielt eine Armee neutrophiler Granulozyten gegen Krebszellen. An den Antikörper gekoppeltes TNF-alpha soll die Zellen zudem tief in solide Tumoren hineinführen.

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.